NEW YORK ─ Entopsis said on Thursday that it is pursuing strategic alternatives for OpsisDx, its urine-based diagnostic testing platform for cancers and other diseases, and it has engaged Berkery Noyes, an investment bank focused on mergers and acquisitions, as its financial advisor.
Entopsis CEO Obdulio Piloto said in a statement it is seeking an established partner that shares its vision and has "an eye towards our long-term interests."
OpsisDx uses a glass slide with 70 hydrogel structures that bind to molecules in a patient's liquid sample and create a colorimetric signature when heated that reflects biometric changes.
In a shift away from conventional RNA and DNA-based approaches to detection, the platform detects chemical signatures using a proprietary array and provides results enabled by machine-learning algorithms, Entopsis said.
Validation studies for the platform initially focused on detecting early-stage cancers, but the Medley, Florida-based firm said it is expanding the platform to detect other types of diseases.